Understanding Cisplatin Resistance Using Cellular Models

UTSePress Research/Manakin Repository

Search UTSePress Research


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Stordal, Britta en_US
dc.contributor.author Davey, Mary en_US
dc.date.accessioned 2009-12-21T02:30:00Z
dc.date.available 2009-12-21T02:30:00Z
dc.date.issued 2007 en_US
dc.identifier 2006015385 en_US
dc.identifier.citation Stordal Britta and Davey Mary 2007, 'Understanding Cisplatin Resistance Using Cellular Models', Taylor & Francis Inc, vol. 59, no. 11, pp. 696-699. en_US
dc.identifier.issn 1521-6543 en_US
dc.identifier.other C1 en_US
dc.identifier.uri http://hdl.handle.net/10453/3728
dc.description.abstract Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts. A series of resis en_US
dc.publisher Taylor & Francis Inc en_US
dc.relation.isbasedon http://dx.doi.org/10.1080/15216540701636287 en_US
dc.title Understanding Cisplatin Resistance Using Cellular Models en_US
dc.parent IUBMB Life en_US
dc.journal.volume 59 en_US
dc.journal.number 11 en_US
dc.publocation Philadelphia en_US
dc.identifier.startpage 696 en_US
dc.identifier.endpage 699 en_US
dc.cauo.name SCI.Medical and Molecular Biosciences en_US
dc.conference Verified OK en_US
dc.for 060199 en_US
dc.personcode 0000025154 en_US
dc.personcode 880134 en_US
dc.percentage 100 en_US
dc.classification.name Biochemistry and Cell Biology not elsewhere classified en_US
dc.classification.type FOR-08 en_US
dc.location.activity ISI:000250516000002 en_US
dc.description.keywords Lung-cancer Cells; Drug-resistance; Thioredoxin Reductase; Ercc1 Expression; Chemotherapy; Gemcitabine; Paclitaxel; Radiation; Agents; Modulation en_US
dc.staffid 880134 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record